BAM
ARQT icon

Byrne Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Byrne Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$930 – 537
2024
Q3 		$930 Hold
100
– – ﹤0.01% 520
2024
Q2 		$942 Hold
100
– – ﹤0.01% 521
2024
Q1 		$991 Hold
100
– – ﹤0.01% 515
2023
Q4 		$302 Hold
100
– – ﹤0.01% 533
2023
Q3 		$1K Hold
100
– – ﹤0.01% 498
2023
Q2 		$1K Sell
100
-100
-50% -$1.11K ﹤0.01% 569
2023
Q1 		$2K Hold
200
– – ﹤0.01% 539
2022
Q4 		$2.96K Hold
200
– – ﹤0.01% 471
2022
Q3 		$4K Hold
200
– – ﹤0.01% 420
2022
Q2 		$4K Hold
200
– – ﹤0.01% 437
2022
Q1 		$4K Buy
200
+150
+300% +$2.54K ﹤0.01% 458
2021
Q4 		$1K Buy
+50
New +$995 ﹤0.01% 514

Other funds holding ARQT

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Byrne Asset Management's ARQT Position: Q4 2024 in Review

Byrne Asset Management sold out of Arcutis Biotherapeutics (ARQT) in Q4 2024, closing a stake of 100 shares — an estimated $930 sold.

Byrne Asset Management first reported a position in ARQT in Q4 2021 and held it in 12 quarters. The position peaked at $4K in Q3 2022. 208 funds tracked by Wall St. Rank hold ARQT as of Q4 2024.

  • Byrne Asset Management reported no remaining Arcutis Biotherapeutics position as of Q4 2024 after selling out during the quarter.
  • Byrne Asset Management sold 100 Arcutis Biotherapeutics shares in Q4 2024, an estimated $930.
  • Byrne Asset Management first reported a position in Arcutis Biotherapeutics in Q4 2021 and held it in 12 quarters.
  • Byrne Asset Management's Arcutis Biotherapeutics position peaked at $4K in Q3 2022.
  • 208 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2024.

Based on Byrne Asset Management's 13F filing for Q4 2024, filed 28 Jan 2025.